Jaguar Health Says It Has Regained Nasdaq Compliance

Jaguar Health Inc JAGX said Monday evening it has regained compliance with all applicable Nasdaq Stock Market listing standards.

Jaguar Health says it received a letter from the Nasdaq on June 21, confirming that the bid price deficiency of Jaguar has been fixed, and that the company is in compliance with all applicable listing standards.

Jaguar Health is a pharmaceutical company focused on developing sustainably derived gastrointestinal products.

Jaguar Health shares traded higher by 1.7% at $4.64 at time of publication.

Related Links:

Jaguar Health Spikes 50% After Subsidiary Receives Preclinical Services From NIAID

Acer Therapeutics Shares Plunge On FDA Complete Response Letter